技术指标
指标
数值
方向
MACD(12,26,9)
0.146
买入
RSI(14)
55.168
中性
STOCH(KDJ)(9,3,3)
44.439
卖出
ATR(14)
4.415
高波动
CCI(14)
27.975
中性
Williams %R
59.347
卖出
TRIX(12,20)
0.480
卖出
StochRSI(14)
0.000
超卖
搜索
Incyte Corp
INCY添加自选
119.470USD
-3.520-2.86%
收盘 07-31 16:00（美东）报价延迟15分钟
23.89B总市值
16.37市盈率 TTM
关键数据
122.190今开
122.670最高
1.83M成交量
16.37市盈率 TTM
13.00市盈率动
--股息TTM
0.92%换手率
122.990昨收
118.440最低
174.09M成交额
732.42市盈率静
4.25市净率
0.00%股息率 TTM
21.88%ROA
112.29052周最高
0.59量比
32.62M净利润
199.95M总股本
7.2963每股收益TTM
0.79Beta
30.82%ROE
63.92552周最低
3.44%振幅
93.73%毛利率
23.89B总市值
2.85回报/风险
1.84%风险率
TradingKey Incyte Corp股票评分
单位: USD 更新时间: 2026-07-31操作建议
Incyte Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名25/155位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价122.34。中期看，股价处于上升通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Incyte Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Incyte Corp亮点
亮点风险
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
业绩高增长
公司营业收入稳步增长，连续3年增长39.12%
利润高增长
公司净利润处于行业前列，最新年度总收入5.14B美元
估值低估
公司最新PE估值16.38，处于3年历史低位
机构减仓
最新机构持股209.33M股，环比减少1.76%
约翰·胡斯曼持仓
明星投资者约翰·胡斯曼持仓，最新持仓市值30.41K
分析师目标
根据
27
位分析师
买入
评级
122.339
目标均价
-3.75%
涨幅空间
Incyte Corp新闻
即将为您带来更多新闻，敬请期待。。。
收益预测
分析师评级
根据
27
位分析师
买入
评级
122.339
目标均价
-3.75%
涨幅空间
强力买入
买入
持有
卖出
强力卖出
同行比较
160
总数
6
中位数
9
平均值
公司名称
评级分布
分析师数
Incyte Corp
INCY
27
安进
AMGN
38
Biogen Inc
BIIB
38
礼来
LLY
34
艾伯维
ABBV
33
辉瑞
PFE
32
1
2
3
...
32
技术指标
移动平均线
指标
数值
方向
MA5
123.682
卖出
MA10
120.160
卖出
MA20
118.293
买入
MA50
109.133
买入
MA100
102.241
买入
MA200
101.258
买入
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Incyte Corp简介
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
公司代码INCY
公司Incyte Corp
CEOMeury (Bill)
网址https://www.incyte.com/
公司股东
相关品种
热门品种
常见问题
Incyte Corp(INCY)的当前股价是多少？
Incyte Corp(INCY)的当前股价是 119.47。
Incyte Corp的股票代码是什么？
Incyte Corp的股票代码是INCY。
Incyte Corp股票的52周最高点是多少？
Incyte Corp股票的52周最高点是112.29。
Incyte Corp股票的52周最低点是多少？
Incyte Corp股票的52周最低点是63.92。
Incyte Corp的市值是多少？
Incyte Corp的市值是23.89B。
现在Incyte Corp(INCY)的股票是买入、持有还是卖出？
根据分析师评级，Incyte Corp(INCY)的总体评级为买入，目标价格为122.34。
Incyte Corp(INCY)股票的每股收益（EPS TTM）是多少
Incyte Corp(INCY)股票的每股收益（EPS TTM）是6.59。